Libtayo Approved for Advanced NSCLC With High PD-L1 Expression
Dec 18, 2023
The FDA approved cemiplimab-rwlc (Libtayo, Regeneron/Sanofi) for the first-line treatment of patients with metastatic or locally advanced or metastatic non-small cell lung cancer (NSCLC) that is unresectable and not amenable to definitive chemoradiation whose tumors have high PD-L1 expression and no EGFR, ALK or ROS1 aberrations.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…